Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04027361 · ClinicalTrials.gov registry record · Phase 2
Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 study, sponsored by Tris Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT04027361 is a Phase 2 study that has completed, run by Tris Pharma. The registered enrollment target is 41 participants.
The verdict
NCT04027361, a Phase 2 study, has completed, sponsored by Tris Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect on driving performance of a single dose of amphetamine extended-release tablets (20 mg/tablet) compared with placebo at 45 minutes and 10 hours post-dose in young adults with ADHD.
Interventions
- DRUG Amphetamine Extended Release (ER) Tablet 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2021-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04027361
The ClinicalTrials.gov registry entry for NCT04027361 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tris Pharma, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Amphetamine Extended Release (ER) Tablet 20 mg is the first listed.
NCT04027361 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04027361 about?
NCT04027361 is a clinical study titled "Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)". The purpose of this study is to assess the effect on driving performance of a single dose of amphetamine extended-release tablets (20 mg/tablet) compared with placebo at 45 minutes and 10 hours post-dose in young adults with ADHD.
What is the current status of trial NCT04027361?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2019-10-01. Estimated completion is 2021-10-15.
What interventions are being tested in trial NCT04027361?
The interventions under investigation include: Amphetamine Extended Release (ER) Tablet 20 mg (DRUG).
Who is sponsoring clinical trial NCT04027361?
This trial is sponsored by Tris Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.